DFTX
Financials
- Market Capitalization 5.51 B
- Employee 106
- Founded 2010
- CEO Robert Barrow
- Website www.definiumtx.com
- Headquarter British Columbia, Canada
- FIGI BBG00F13HYQ7
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 1275 |  LGND Ligand Pharmaceuticals Incorporated - Common Stock | 280.49 USD | -1.42% | -2.02% | -4.80% | +49.90% | 5.59 B USD | ||
| 1279 |  CRSP CRISPR Therapeutics AG - Common Shares | 57.72 USD | -2.78% | -1.52% | +21.72% | +8.97% | 5.58 B USD | ||
| 1348 |  ACAD ACADIA Pharmaceuticals Inc. - Common Stock | 29.11 USD | -2.09% | -1.32% | +11.40% | +12.35% | 5.02 B USD | ||
| 1399 |  DYN Dyne Therapeutics, Inc. - Common Stock | 25.07 USD | -3.91% | -4.06% | -3.43% | +7.09% | 4.68 B USD |
Frequently asked questions about Definium Therapeutics, Inc. Common Shares
What is the Definium Therapeutics, Inc. Common Shares stock price today?
The current price of Definium Therapeutics, Inc. Common Shares (DFTX) is 40.98. Over the past 24 hours, the stock has changed by -6.48%. Follow the DFTX chart for real-time price dynamics.
What is the stock ticker of Definium Therapeutics, Inc. Common Shares?
Definium Therapeutics, Inc. Common Shares trades under the ticker DFTX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Definium Therapeutics, Inc. Common Shares stock going up?
DFTX has changed by -7.64% over the last week, -2.43% over the last month, and +171.21% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Definium Therapeutics, Inc. Common Shares?
Definium Therapeutics, Inc. Common Shares currently has a market capitalization of 5.51 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Definium Therapeutics, Inc. Common Shares earnings last quarter?
Last quarter, Definium Therapeutics, Inc. Common Shares reported earnings of -1.44 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Definium Therapeutics, Inc. Common Shares revenue for the last quarter?
Definium Therapeutics, Inc. Common Shares reported quarterly revenue of -32 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Definium Therapeutics, Inc. Common Shares net income for the last quarter?
Definium Therapeutics, Inc. Common Shares reported net income of -158.99 M for the last quarter. The previous quarter showed -77.1 M, which means net income changed by -106.21%.
How many employees does Definium Therapeutics, Inc. Common Shares have?
As of the latest available data, Definium Therapeutics, Inc. Common Shares has 106 employees. Workforce size can provide additional context about the company's scale and operations.
What is Definium Therapeutics, Inc. Common Shares EBITDA?
Definium Therapeutics, Inc. Common Shares EBITDA is -76.47 M, and its EBITDA margin is 238.98 K%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Definium Therapeutics, Inc. Common Shares stock?
You can buy Definium Therapeutics, Inc. Common Shares (DFTX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Definium Therapeutics, Inc. Common Shares stock?
Investing in Definium Therapeutics, Inc. Common Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the DFTX chart and related analysis on metatrader.com as part of your research.